Visual Cortical Alterations and their Association with Negative Symptoms in Antipsychotic-Naïve First Episode Psychosis.
First episode psychosis
Negative symptoms
Visual cortex
Journal
Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
19
11
2019
revised:
17
03
2020
accepted:
26
03
2020
pubmed:
24
4
2020
medline:
18
11
2020
entrez:
24
4
2020
Statut:
ppublish
Résumé
Visual perceptual and processing deficits are common in schizophrenia and possibly point towards visual pathway alterations. However, no studies have examined visual cortical morphology in first-episode psychosis (FEP). In an antipsychotic-naïve FEP population, we investigated primary visual (V1), association area (V2), and motion perception (V5/MT) morphology compared to controls. We found reductions in the V1 and V2 areas, greater MT area and lower MT thickness in the FEP-schizophrenia group when compared to controls. Also, lower MT thickness was associated with worse negative symptoms. Our results shed light on this poorly studied area of visual cortex morphology in FEP.
Identifiants
pubmed: 32325384
pii: S0165-1781(19)32337-6
doi: 10.1016/j.psychres.2020.112957
pmc: PMC7333935
mid: NIHMS1588113
pii:
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
112957Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002542
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000056
Pays : United States
Organisme : NIMH NIH HHS
ID : K02 MH001180
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH045156
Pays : United States
Organisme : NIMHD NIH HHS
ID : L32 MD014380
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None
Références
Schizophr Res. 2007 May;92(1-3):197-206
pubmed: 17350226
Neuropsychopharmacology. 2013 Dec;38(13):2607-12
pubmed: 23842600
Cereb Cortex. 2008 Aug;18(8):1973-80
pubmed: 18079129
Curr Opin Psychiatry. 2005 Mar;18(2):151-7
pubmed: 16639168
Brain. 1994 Oct;117 ( Pt 5):1023-38
pubmed: 7953586
Cereb Cortex. 2015 Jun;25(6):1608-17
pubmed: 24408955
Arch Gen Psychiatry. 2005 Nov;62(11):1218-27
pubmed: 16275809
Schizophr Bull. 2003;29(4):757-69
pubmed: 14989413
Arch Gen Psychiatry. 2004 Jan;61(1):17-22
pubmed: 14706940
Biol Psychiatry. 2010 Jul 1;68(1):41-50
pubmed: 20609836
J Integr Neurosci. 2009 Jun;8(2):175-202
pubmed: 19618486
Nat Rev Neurosci. 2003 Mar;4(3):219-29
pubmed: 12612634
Psychiatry Res Neuroimaging. 2020 May 30;299:111061
pubmed: 32145500
F1000Prime Rep. 2014 Jul 08;6:57
pubmed: 25184047
Schizophr Bull. 2009 Jan;35(1):233-43
pubmed: 18222929
Mol Psychiatry. 2018 Apr;23(4):932-942
pubmed: 28461699
Arch Gen Psychiatry. 2002 Nov;59(11):1011-20
pubmed: 12418934
Neuroimage Clin. 2017 Apr 18;15:45-52
pubmed: 28480163
Mol Psychiatry. 2009 Oct;14(10):976-86
pubmed: 18607377
Schizophr Bull. 2020 Jan 4;46(1):43-53
pubmed: 31112601
Mol Psychiatry. 2018 May;23(5):1261-1269
pubmed: 29038599
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
Front Integr Neurosci. 2015 Apr 01;9:21
pubmed: 25883556
Schizophr Res. 2005 Jun 15;75(2-3):183-92
pubmed: 15885509
Mod Probl Pharmacopsychiatry. 1990;24:73-88
pubmed: 2336066
Cereb Cortex. 2013 Nov;23(11):2521-30
pubmed: 22892423
Am J Psychiatry. 2003 Jul;160(7):1298-304
pubmed: 12832245
Front Psychol. 2013 Jul 24;4:466
pubmed: 23898311
Am J Psychiatry. 2001 Nov;158(11):1818-26
pubmed: 11691687
Front Psychiatry. 2018 Mar 12;9:69
pubmed: 29593580
Am J Psychiatry. 2019 Jul 1;176(7):564-572
pubmed: 31164007
Psychol Med. 2019 Jul;49(10):1740-1748
pubmed: 30178729
Biol Psychiatry. 2018 Nov 1;84(9):644-654
pubmed: 29960671
Am J Psychiatry. 2005 Mar;162(3):495-506
pubmed: 15741466